Hypertension and Atrial Fibrillation-Reference-Cited by-同舟云学术

Hypertension and Atrial Fibrillation

Published:2018-01-19 Issue:2 Volume:122 Page:352-368
ISSN:0009-7330
Container-title:Circulation Research
language:en
Short-container-title:Circ Res

Author:

Verdecchia Paolo¹,Angeli Fabio¹,Reboldi Gianpaolo¹

Affiliation:

1. From the Struttura Complessa di Medicina, Dipartimento di Medicina, Ospedale di Assisi, Italy (P.V.); and Struttura Complessa di Cardiologia e Fisiopatologia Cardiovascolare, Dipartimento di Cardiologia (F.A.) and Dipartimento di Medicina Interna (G.R.), Università di Perugia, Italy.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Physiology

Reference172 articles.

1. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data

2. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

3. Worldwide prevalence of hypertension

4. Global Disparities of Hypertension Prevalence and Control

5. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

Cited by 167 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond pulmonary vein isolation: approaches to treat patients with persistent atrial fibrillation;Expert Review of Cardiovascular Therapy;2024-09-12

2. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation;Heart Rhythm;2024-09

3. Could the Early Detection of Atrial Fibrillation Reduce the Risk of Developing Dementia?;Biomedicines;2024-08-22

4. Determinants of adverse outcomes following patent foramen ovale closure in elderly patients;EuroIntervention;2024-08

5. Analysis of hemorrhagic drug-drug interactions between P-gp inhibitors and direct oral anticoagulants from the FDA Adverse Event Reporting System;Expert Opinion on Drug Safety;2024-07-08